ALK-Abelló A/S

CPSE:ALK B Stock Report

Market Cap: DKK 48.1b

ALK-Abelló Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Peter Halling

Chief executive officer

DKK 18.4m

Total compensation

CEO salary percentage39.21%
CEO tenure3.1yrs
CEO ownershipn/a
Management average tenure3yrs
Board average tenure5.9yrs

Recent management updates

Recent updates

Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity

Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?

ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly

Jan 23
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly

Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects

Dec 08
Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects

ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets

Nov 15
ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Oct 11
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear

Jul 23
ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear

ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly

Jun 17
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly

Is There An Opportunity With ALK-Abelló A/S' (CPH:ALK B) 24% Undervaluation?

May 04
Is There An Opportunity With ALK-Abelló A/S' (CPH:ALK B) 24% Undervaluation?

Here's Why ALK-Abelló (CPH:ALK B) Has Caught The Eye Of Investors

Apr 16
Here's Why ALK-Abelló (CPH:ALK B) Has Caught The Eye Of Investors

Here's Why ALK-Abelló (CPH:ALK B) Can Manage Its Debt Responsibly

Mar 12
Here's Why ALK-Abelló (CPH:ALK B) Can Manage Its Debt Responsibly

Earnings Update: ALK-Abelló A/S (CPH:ALK B) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 22
Earnings Update: ALK-Abelló A/S (CPH:ALK B) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
User avatar

Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings

The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.

CEO Compensation Analysis

How has Peter Halling's remuneration changed compared to ALK-Abelló's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

DKK 1b

Jun 30 2025n/an/a

DKK 999m

Mar 31 2025n/an/a

DKK 937m

Dec 31 2024DKK 18mDKK 7m

DKK 815m

Compensation vs Market: Peter's total compensation ($USD2.91M) is about average for companies of similar size in the Danish market ($USD2.94M).

Compensation vs Earnings: Insufficient data to compare Peter's compensation with company performance.

CEO

Peter Halling (48 yo)

3.1yrs
Tenure
DKK 18,365,000
Compensation

Mr. Peter Halling is President & Chief Executive Officer of ALK-Abelló A/S from 2023. Mr. Peter Halling served as Chief Executive Officer at Fertin Pharma A/S since August 2020. He has an extensive experie...

Leadership Team

NamePositionTenureCompensationOwnership
Peter Halling
President & CEO3.1yrsDKK 18.37mno data
Claus Solje
Executive VP2.7yrsDKK 8.68mno data
Søren Niegel
Member of Management Board13.8yrsDKK 7.58m0.039%
DKK 18.7m
Henriette Mersebach
Executive VP Research & Development & Member of Management Board2.9yrsDKK 6.54mno data
Katja Thalund
Senior Project Directorno dataDKK 350.00kno data
Lise Maerkedahl
Project Director of Global Research & Employee-elected Directorno dataDKK 350.00kno data
Per Plotnikof
VP of Corporate Communicationsno datano datano data
Jacob Glenting
Senior Vice President of Global Strategy & Corporate Development2.1yrsno datano data
Lika Thiesen
Executive Vice President of Global People & Organisation2.1yrsno datano data
Hendrik Kees Nolte
Senior Vice President of Research & Development - North America and International Markets8.9yrsno datano data
Christian Houghton
Executive Vice President of Product Supply7.1yrsno datano data
Peter Andersen
Senior Vice President of Global Research & Drug Discoveryno datano datano data
3.0yrs
Average Tenure
54yo
Average Age

Experienced Management: ALK B's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Katja Thalund
Senior Project Director15.1yrsDKK 350.00kno data
Lise Maerkedahl
Project Director of Global Research & Employee-elected Director2.9yrsDKK 350.00kno data
Jesper Hoiland
Independent Director2.9yrsDKK 475.00kno data
Lene Skole-Sorensen
Vice Chairman of the Board12.1yrsDKK 900.00kno data
Anders Hedegaard
Independent Chairman of the Board5.9yrsDKK 1.30mno data
Lars Holmqvist
Director10.9yrsDKK 475.00kno data
Gitte Aabo
Independent Director4.9yrsDKK 538.00kno data
Alan Main
Independent Director3.9yrsDKK 450.00kno data
Bertil Lindmark
Independent Director4.9yrsDKK 500.00kno data
Nanna Carlson
Employee Representative Director6.9yrsDKK 350.00kno data
Johan Smedsrud
Employee Representative Director6.9yrsDKK 350.00kno data
5.9yrs
Average Tenure
62yo
Average Age

Experienced Board: ALK B's board of directors are considered experienced (5.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/07 06:46
End of Day Share Price 2026/02/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ALK-Abelló A/S is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Jesper IlsoeCarnegie Investment Bank AB
Jesper IlsøeDNB Carnegie